ENDO 2026 attendees who catch the session, “Weight Loss: Friend or Foe for Bone & Muscle?” will be in for a treat as three experts weigh in on the impact of various weight loss therapies on muscle and bone. Pharmacological, surgical, and even lifestyle impacts will be discussed and debated in this Sunday morning symposium....
At ENDO 2026, taking place June 13 – 16 in Chicago, “Beyond Basic DXA” is set to challenge how clinicians think about bone health assessment. Angela M. Cheung, MD, PhD, a professor of medicine at the University Health Network and the University of Toronto, will lead “Beyond Basic DXA” on Day 4 (Monday, June 15),...
Effective long-term management of osteoporosis requires a carefully choreographed sequence of medications, as certain drug transitions can significantly enhance or inadvertently undermine bone density, according to a clinical review published by researchers at Aarhus University. The article, “Approach to the Patient—Transitions in Osteoporosis Therapy,” appearing in The Journal of Clinical Endocrinology & Metabolism, emphasizes that...
New clinical research has identified a significant delay in skeletal maturation among children with X-linked hypophosphatemia (XLH), with male patients experiencing notably more pronounced delays than females. The study, published in Journal of The Endocrine Society, highlights a significant gap between chronological age and bone age (BA). These findings provide clinicians with more precise benchmarks...
Early-life exposure to per- and polyfluoroalkyl substances (PFAS) may influence how children’s bones develop during adolescence, according to new research published in the Journal of the Endocrine Society. PFAS are synthetic chemicals found in water, food and everyday products. These “forever chemicals,” many of which persist in the environment and in the human body, may interfere with normal development, including bone growth. “Adolescence is a key period for...
Scientists have uncovered a new, fundamental mechanism behind the severe skeletal abnormalities seen in Jansen metaphyseal chondrodysplasia (JMC), a rare genetic disorder characterized by short-limbed dwarfism. A new study reveals that the causative H223R-PTH1R gene mutation directly impairs mature bone cells, known as osteocytes, leading to bone structural irregularities and poor quality, a finding that...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...